Exclusive interviews with leading policymakers that convey the true policy message that impacts markets.
Reporting on key macro data at the time of release.
Real-time insight on key fixed income and fx markets.
- Emerging MarketsEmerging Markets
Real-time insight of emerging markets in CEMEA, Asia and LatAm region
- Political RiskPolitical Risk
Intelligence on key political and geopolitical events around the world.
- About Us
Sign up now for free access to this content.
Please enter your details below and select your areas of interest.
The European Medicines Agency (EMA) has confirmed this morning that it is launching a rolling review of China's Sinovac COVID-19 vaccine for potential use in the EU.
- Link to statement: https://www.ema.europa.eu/en/news/ema-starts-rolli...
- "EMA will evaluate data as they become available to decide if the benefits outweigh the risks. The rolling review will continue until enough evidence is available for a formal marketing authorisation application."
- So far, the EU has not approved the use of any vaccine not developed in the bloc, the US, or the UK, with approval still pending for Russia's Sputnik V vaccine as well.
- Some EU countries, notably Hungary, have already begun to use non-EMA approved vaccines, with Sputnik V and China's Sinopharm vaccine already in use in the country.